FRM
SIOX

Fox Run Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Fox Run Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,019
Closed -$127K – 989
2017
Q4 		$127K Buy
+3,019
New +$135K 0.04% 615
2017
Q3 		– Sell
-2,175
Closed -$404K – 931
2017
Q2 		$404K Buy
+2,175
New +$381K 0.14% 306

Other funds holding SIOX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fox Run Management's SIOX Position: Q1 2018 in Review

Fox Run Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2018, closing a stake of 3,019 shares — an estimated $127K sold.

Fox Run Management first reported a position in SIOX in Q2 2017 and held it in 2 quarters. The position peaked at $404K in Q2 2017. 81 funds tracked by Wall St. Rank hold SIOX as of Q1 2018.

  • Fox Run Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Fox Run Management sold 3,019 Sio Gene Therapies Inc. Common Stock shares in Q1 2018, an estimated $127K.
  • Fox Run Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Fox Run Management's Sio Gene Therapies Inc. Common Stock position peaked at $404K in Q2 2017.
  • 81 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2018.

Based on Fox Run Management's 13F filing for Q1 2018, filed 17 Apr 2018.